The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS&lt;sup&gt;G12D&lt;/sup&gt; Inhibitor Treatment. Here, BCL2L1 is linked to pancreatic ductal adenocarcinoma.